House passes FDA manufacturing compliance bill
June 01, 2012
The House of Representatives recently passed manufacturing legislation
that would increase inspections of overseas drug manufacturing sites in countries such as China and India.
The bill, passed in a 387-5 vote, would grant the U.S. Food and Drug Administration (FDA) more power to crack down on tainted foreign-manufactured pharmaceuticals.
"I am so proud we passed a bipartisan bill to create an early warning system so the FDA, drug companies and doctors can better respond to shortages, quickly and efficiently," said Representative Diana DeGette, a Colorado Democrat, in a statement
. DeGette co-sponsored the legislation with Florida Republican Representative Tom Rooney.
As The Republic
notes, the FDA's U.S.-focused factory inspections do not take into account the fact that many companies have moved their operations abroad for cost reasons. Indeed, approximately 80 percent of U.S. medicinal ingredients are made overseas, according to the news source.
FDA commissioner Margaret Hamburg lauded the passage of the manufacturing compliance
bill, saying it "signals support for innovation and access to safe and effective medical products," as quoted by The Associated Press